Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity inhigh-risk B-cell acute lymphoblastic leukemia

(2020) Chunhua Song et al.   BLOOD

“JANUS” EFFICACY OF CX-5011: CK2 INHIBITION AND METHUOSIS INDUCTION BY INDEPENDENT MECHANISMS

(2020) Claudio D’Amore et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

A journey through the cytoskeleton with protein kinase CK2

(2019) Claudio D’Amore et al.   CURRENT PROTEIN & PEPTIDE SCIENCE

Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide

(2019) Margaux Colin et al.   Cancers

CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells

(2019) Eduardo Silva-Pavez et al.   Cell Death & Disease

Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia

(2019) Anna Richter et al.   BMC CANCER

Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer

(2019) Minkyu Jung et al.   Gastric Cancer

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later

(2019) Pawel Robak et al.   Drugs in research & development

Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells

(2019) PATRYCJA WIŃSKA et al.   ANTICANCER RESEARCH

The effect of ionizing radiation on the subcellular localization and kinase activity of protein kinase CK2 in human non-small cell lung cancer cells

(2019) Qianwen Li et al.   INTERNATIONAL JOURNAL OF RADIATION BIOLOGY

Role of protein kinase CK2 in antitumor drug resistance

(2019) Christian Borgo et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide

(2019) Ryan T. Nitta et al.   ONCOGENE

Deciphering the role of protein kinase CK2 in the maturation/stability of F508del-CFTR

(2019) Claudio D'Amore et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Protein Kinase CK2 Subunits Differentially Perturb the Adhesion and Migration of GN11 Cells: A Model of Immature Migrating Neurons

(2019) Antonella Lettieri et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells

(2019) Giovanni Di Maira et al.   Oncogenesis

Inhibition of Casein Kinase II by CX-4945, But Not Yes-associated protein (YAP) by Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma

(2019) Xiangyu Liu et al.   Translational Oncology

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?

(2018) Benjamin L. Lampson et al.   Expert Review of Hematology

Dependence of HSP27 cellular level on protein kinase CK2 discloses novel therapeutic strategies

(2018) Christian Borgo et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism

(2018) Jomnarong Lertsuwan et al.   Cancers

Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma

(2018) Kais Zakharia et al.   Translational Oncology

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer

(2017) Pasi A. Jänne et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells

(2017) Amber L. Rowse et al.   JOURNAL OF NEURO-ONCOLOGY

EGFR heterogeneity and implications for therapeutic intervention in glioblastoma

(2017) Eskil Eskilsson et al.   NEURO-ONCOLOGY

Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2.

(2017) R. F. Marschke et al.   JOURNAL OF CLINICAL ONCOLOGY

TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: A study on human primary cell cultures

(2017) Anna Maria Lustri et al.   PLoS One

CK2 modulates adipocyte insulin-signaling and is up-regulated in human obesity

(2017) Christian Borgo et al.   Scientific Reports

Molecular Pathways: Emergence of Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and Repair Pathways in Cancer Cells

(2016) A. J. Rabalski et al.   CLINICAL CANCER RESEARCH

CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells

(2016) Haiwei Lian et al.   HAEMATOLOGICA

Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies

(2016) Valentina Salizzato et al.   Oncotarget

CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells

(2016) Haiwei Lian et al.   HAEMATOLOGICA

Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia

(2015) C. Song et al.   BLOOD

MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer

(2015) Yansong Bian et al.   International Journal of Biological Sciences

Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1

(2015) Edwin Jousma et al.   PEDIATRIC BLOOD & CANCER

Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance

(2015) Malin Wickström et al.   Nature Communications

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB

(2015) Francesca Buontempo et al.   Oncotarget

A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer

(2015) Harsh B. Pathak et al.   PLoS One

c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells

(2014) J. E. Roderick et al.   BLOOD

CK2α phosphorylates DBC1 and is involved in the progression of gastric carcinoma and predicts poor survival of gastric carcinoma patients

(2014) Jun Sang Bae et al.   INTERNATIONAL JOURNAL OF CANCER

Mining CK2 in Cancer

(2014) Charina E. Ortega et al.   PLoS One

Pharmacokinetic characterization of CK2 inhibitor CX-4945

(2013) You Hwa Son et al.   ARCHIVES OF PHARMACAL RESEARCH

Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma

(2013) Y. Zheng et al.   CLINICAL CANCER RESEARCH

Kinase CK2 Inhibition: An Update

(2013) G. Cozza et al.   CURRENT MEDICINAL CHEMISTRY

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity

(2013) Laura Quotti Tubi et al.   Journal of Hematology & Oncology

Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia

(2013) L R Martins et al.   LEUKEMIA

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

(2013) R C Prins et al.   LEUKEMIA

Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: Biochemical evidence and therapeutic perspectives

(2013) Christian Borgo et al.   Molecular Oncology

Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells

(2013) Sabrina Manni et al.   PLoS One

B cell receptor signaling in chronic lymphocytic leukemia

(2013) Jan A. Burger et al.   TRENDS IN IMMUNOLOGY

Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells

(2012) Joshua Bliesath et al.   CANCER LETTERS

Small heat shock proteins HSP27 (HspB1), αB-crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death

(2012) Julie Acunzo et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy

(2012) A. Siddiqui-Jain et al.   MOLECULAR CANCER THERAPEUTICS

Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells

(2012) Sofia Zanin et al.   PLoS One

Unprecedented Selectivity and Structural Determinants of a New Class of Protein Kinase CK2 Inhibitors in Clinical Trials for the Treatment of Cancer

(2011) Roberto Battistutta et al.   BIOCHEMISTRY

Structural Determinants of CX-4945 Derivatives as Protein Kinase CK2 Inhibitors: A Computational Study

(2011) Hongbo Liu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

(2011) Fabrice Pierre et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Overexpression of Nuclear Protein Kinase CK2 β Subunit and Prognosis in Human Gastric Carcinoma

(2010) Kai-Yuan Lin et al.   ANNALS OF SURGICAL ONCOLOGY

Emergence of protein kinase CK2 as a key target in cancer therapy

(2010) Janeen H. Trembley et al.   BIOFACTORS

414 Clinical pharmacokinetics and pharmacodynamics of CX-4945, a novel inhibitor of protein kinase CK2: Interim report from the phase 1 clinical trial

(2010) C.S. Padgett et al.   EJC SUPPLEMENTS

Structural basis of CX-4945 binding to human protein kinase CK2

(2010) Andrew D. Ferguson et al.   FEBS LETTERS

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

(2010) Fabrice Pierre et al.   JOURNAL OF MEDICINAL CHEMISTRY

MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivo

(2010) Y. C. Henderson et al.   MOLECULAR CANCER THERAPEUTICS

Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis

(2009) Mauro Salvi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Addiction to protein kinase CK2: A common denominator of diverse cancer cells?

(2009) Maria Ruzzene et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Protein Kinase CK2 in Health and Disease

(2009) N. A. St-Denis et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity

(2009) Y. Perera et al.   MOLECULAR CANCER THERAPEUTICS

Src kinases as therapeutic targets for cancer

(2009) Lori C. Kim et al.   Nature Reviews Clinical Oncology

From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage

(2008) S. Giordano et al.   CURRENT MEDICINAL CHEMISTRY

Too much of a good thing: The role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2

(2007) James S. Duncan et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS